QIAGEN Board Accepts EQT's €46.50/Share Takeover, Valuing Company at $12.1B
QGEN sits 55% above its 52-week low of $32.53 on elevated volume (4.6× avg).
Summary
QIAGEN's supervisory and managing boards unanimously approved an all-cash takeover by EQT Private Equity at €46.50 a share, valuing the company at roughly €10.8 billion ($12.1 billion) including $1.1 billion of net debt. The price is a 40.3% premium to the July 8 close before takeover interest surfaced and a 46.9% premium to the three-month VWAP through that date. Crown NL Bidco, indirectly controlled by EQT XI, is the acquirer, with Abu Dhabi Investment Authority and CPP Investments as co-investors; EQT has committed equity and debt financing and the deal carries no financing condition. This formalizes the advanced talks reported October 20-21 and follows the September reports of private-equity interest from TPG and Bain. Closing is targeted for mid-2027 and needs holders of 50% of shares plus one to tender, plus regulatory clearances; the Frankfurt and New York listings will be terminated after closing. QGEN closed at $50, up 2.25%, and traded at $50.14 overnight — the small gap to the €46.50 offer implies the market is pricing deal and timing risk rather than upside.
At the time of this announcement, QGEN was trading at $50.27 on NYSE in the Life Sciences sector, with a market capitalization of approximately $10.3B. The 52-week trading range was $32.53 to $57.82. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: dpa-AFX.